Dr. Carman Giacomantonio, Sona's CMO, guides viewers from cancer fundamentals through the science behind Targeted Hyperthermia Therapy and into Sona's active clinical program: the IGNITE-THT and PRIME-THT clinical studies. Each episode builds the scientific case for why a THT + immunotherapy combination therapy may improve outcomes for melanoma patients.
Latest episode: Heat, Immunity and Cancer
In this episode of Carman’s Corner, Dr. Carman Giacomantonio explains why fever is the immune system’s natural alarm. We explore how heat activates immune responses—and how focusing that response inside a tumor may unlock immunity where it’s otherwise absent.
Episode 1: How does cancer happen?
Dr. Carman breaks down how cancer starts and explores the science behind Sona’s innovative Targeted Hyperthermia Therapy.
Episode 2: Cancer and our Immune System
Dr. Carman breaks down how Learn how cancer uses immune “checkpoints” to escape detection in this week’s Carman’s Corner.
Episode 3: How our immune system responds to cancer?
Dr. Carman explains how the immune system recognizes and responds to cancer. The immune system has two main “arms”: the innate arm and the adaptive arm.
Episode 4: How science is unlocking new possibilities in cancer treatment?
Dr. Carman delves into the fundamentals of immunotherapy, how modern medicine empowers the immune system to fight cancer by overcoming the body’s own checks and balances.
Episode 5: How Modern Immunotherapy Targets Cancer
Dr. Carman Giacomantonio breaks down how the immune system recognizes and attacks cancer, and why immune checkpoints can both protect us and hinder treatment.
Episode 6: Providing more Targets for the Immune System
Dr. Carman Giacomantonio explains how immune checkpoint blockades work in cancer therapy, why they often fail, and how Sona’s targeted hyperthermic therapy aims to boost immune recognition and killing of cancer cells.
Episode 7: Why Immunotherapy Fails: Inside the Tumor Microenvironment
In this episode of Carman’s Corner, Dr. Carman Giacomantonio explains why immunotherapy often fails and explores the critical role of the tumor microenvironment in blocking immune response.